RE:RE:NASHIndustry-wise, the NASH watchers are basically all looking at Madrigal who, upon completion of their Phase 3 trial toward year end, may get the very first approval for a drug in this indication. It's not a slam-dunk and the probability of success by analysts is roughly around 60% thinking it will meet all the primary endpoints and get approved and 40% thinking it may not meet them.
I think if Madrigal passes the endpoints, it will reignite interest in this massive potential market. The Madrigal drug is also an upstream fat-buster type, a la Tesamorelin. Baring that, it will be slow moving in the NASH therapy market it seems.
LouisW wrote: I dont know what was going on on the post. Let me post again.
To me, the NASH evolution is interesting. On the corporate slide posted on March 2022 said that External US based biopharma advisory firm retained to assist in identifying potential partner. And the latest slide said that "Actively pursuing discussions with companies that have interest, capabilities and resources". Obviously, they want to work with big pharma and they have already find their target. The ongoing discussion probably focusing on the trial design, data or maybe contract details.
Hopes as soo as the water issue is solved, the PR regarding the partnership on NASH can be anounced followed by skyrocketing share price.